FDA Committee Seeks Feedback on Avacopan Ahead of Public Meeting

FDA Committee Seeks Feedback on Avacopan Ahead of Public Meeting

291602

FDA Committee Seeks Feedback on Avacopan Ahead of Public Meeting

A committee of the U.S. Food and Drug Administration (FDA) is holding a public meeting to discuss the potential approval of avacopan for the treatment of ANCA-associated vasculitis (AAV). During the meeting of the FDA’s Arthritis Advisory Committee, members will review safety and efficacy data of Chemocentryx’s avacopan to provide advice and recommendations on whether this treatment should be approved by the regulatory agency. The online meeting, which is open to the public, will be…

You must be logged in to read/download the full post.